All News

Two people dead after receiving potentially contaminated Moderna COVID-19 vaccines in Japan; Biogen offers its controversial and expensive Alzheimer disease treatment for free to boost prescriptions; COVID-19 infection with the Delta variant may more than double the risk of hospitalization.

The meta-analysis collected findings from 11 studies, from which researchers determined statistical heterogeneity regarding the incidence of GVHD between patients receiving only HSC transplantation or only killer cell therapy, and patients receiving HSC transplantation in addition to killer cell therapy.

A simple intervention to get people to use salt substitute and cut their stroke risk—along with other cardiovascular events—has implications for developing countries with diets high in salt that have high rates of chronic disease.

Switching patients with asthma to a biologic medication purely because that patient is not adherent to inhaled medications gets in the way of a physician's goal of being good stewards of patient care and finances, said William "Andy" Nish, MD.

A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.

In patients with heart failure and diabetes, sotagliflozin can lower glucose quite well, even when patients are facing suboptimal glomerular filtration rates, noted Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School.

In a paper being presented during ESC Congress 2021, authors from the University of Copenhagen use a registry to mimic 2 well-known trials, finding explanations for some, but not all, of the gap in risk reduction between them.

Both REDUCE-IT and STRENGTH recruited people with very high triglycerides and tested different formulations of omega-3 fatty acids, but the results were different. About 12% of the difference can be explained, noted Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, but 13% cannot be, given that REDUCE-IT had a 25% reduced risk of atherosclerotic cardiovascular disease.

There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.

Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.

This study is one of only a handful to explore barriers to pulmonary rehabilitation in Iran for patients with chronic obstructive pulmonary disease (COPD).

A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.

Results of a score-matched analysis showed individuals with hepatocellular cancer reported poor mental health as time progressed after diagnosis.

Research shows higher levels of interleukin 6 in patients with chronic coronary syndrome were associated with an increased risk of cardiovascular events in patients with chronic kidney disease.

The use of potentially inappropriate medications (PIMs) by older adults appeared to be linked to a greater risk of frailty, although the researchers said further work is needed.

Findings from 5 studies presented on day 1 of ESC Congress 2021 indicate that there is still much to be learned on the complex interaction among COVID-19 infection, cardiovascular care, and heart failure.

Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the anticipation for more biosimilars to enter the oncology market and the current level of interest in the pipeline.

Patients with multiple sclerosis (MS) who have recovered from COVID-19 and received the B-cell depleting therapy ocrelizumab for at least 1 year were observed to still have T-cell responses.

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses how greater visual needs are contributing to adverse eye health in younger populations.

EMPEROR-Preserved represents the first trial to show unequivocal benefits of any drug on major heart failure outcomes in patients with heart failure and preserved ejection fraction, the lead investigator said.

The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.

A roundup of the latest news in sleep research reported across MJH Life Sciences™.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

FDA halts sale of more than 50,000 flavored e-cigarette products; health systems in Idaho and Oregon struggle to meet the influx of patients with COVID-19; drop in breast cancer screening rates seen throughout pandemic.

The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.

A recent study found that older age, male gender, lack of surgical resection or chemotherapy, and late-stage disease may be poor prognostic factors for diffuse large B-cell lymphoma (DLBCL) of the urinary tract.

Although there is an established link between type 2 myocardial infarction (T2MI) and elevated rates of cardiovascular events, less is known about the connection between T2MI and heart failure—which this new study investigated.